Approved uses of platform data

The following research proposals include both those approved by the platform’s independent Data Access Committee and those which are ISARIC Partner Analyses. Please review these proposals before submitting a Data Access Request. In the interest of maximising the production of evidence to reduce the impact of COVID-19, the platform aims to avoid unnecessary duplication of analyses.  

Creative rendition of SARS-COV-2 virus particles. Note: not to scale
Credit: National Institute of Allergy and Infectious Diseases, NIH

DAC approved proposals

Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands

The emergence of COVID-19 has had a tremendous impact on global health and international society. In a Dutch multicentre collaboration, the research team describe the clinical characteristics of patients who were admitted to Dutch hospitals with COVID-19 and assess the clinical outcomes of these patients. The objectives of the research are: to describe the clinical features of patients who were admitted to Dutch hospitals with COVID-19, including demographics, admission characteristics (symptoms, signs, and laboratory), treatment-related variables and complications; to assess patient outcomes and determine associations between demographic (including age, gender, ethnicity, comorbidity), admission characteristics (including inclusion O2 saturation, GCS, creatinine, CRP) and patient outcomes.

Read full application

ISARIC Partner Analyses

Johns Hopkins University School of Medicine, USA – Neurological manifestation and outcome for patients admitted to hospital with COVID-19

This is a multi-centre international observational study in patients with COVID-19 to report and characterize the prevalence, risk factor, and outcome of neurological manifestations. Recent findings suggested that COVID-19 patients may also develop neurological symptoms by mechanisms not yet elucidated. To date, neurological manifestations have been characterised into three main areas: central nervous system disorders, peripheral nervous system disorder and skeletal muscle symptoms. It is well known that neurological outcome in critically ill patients can be influenced by the development of secondary brain damage, and that COVID-19 patients frequently present hypoxia, as a result of severe respiratory distress, hypotension, and microvascular abnormalities. It can be hypothesized that one of the possible mechanisms involved in neurological manifestations of COVID-19 patients could be the promotion of neuroinflammation and excitotoxicity with increased permeability of the blood brain barrier. The aim of this observational multi-centre international study is to identify the prevalence of neurological manifestations in critically ill confirmed COVID-19 patients and to assess risk factors and outcomes of neurological complications of COVID-19.

Read the full application


University of Queensland, Australia and Universidad Mayor de San Simon, Cochabamba, Bolivia – Acute Kidney Injury in COVID-19

Close to half of all patients admitted to hospital with COVID 19 have kidney involvement and a variable proportion, between 0.5 to 36%, will develop acute kidney injury (AKI) during their hospital stay. AKI is especially common among patients who require mechanical ventilation, with much of its burden observed in the intensive care unit setting and around the time of intubation. In this context, development of AKI has been characterised as both a marker of disease severity as well as a negative prognostic indicator. To date, studies looking at kidney disease in COVID 19 patients have been limited to single centre or regional cohorts mostly from China, Europe or USA, which fail to reflect the global experience of kidney disease, particularly in low and middle income countries where the burden of disease may be much higher and the therapeutic resources limited. This analysis has three aims: to characterise patients with COVID-19 who develop AKI; to identify the temporal profile of AKI in patients with COVID-19 throughout the hospital journey; to develop a predictive machine learning model for AKI in COVID-19, using data from predominantly upper middle-income countries, and externally validate this model in a LMIC setting (Latin America).

Read full application

British Columbia Children's Hospital, Canada and Universidad De La Sabana, Columbia - Analysis of the ISARIC International COVID-19 Critically Ill Cohort

There are few international cohorts of the critically-ill patient population described in the literature and this collaborative project aims to address this gap. The study aims to describe the first and subsequent waves of the COVID-19 pandemic by: summarising the demographic characteristics and clinical features of ~16,000 critically ill patients of any age, admitted to hospital with COVID-19 across high-income and low- and middle-income settings, across temporal phases of the pandemic; describing clinical outcomes (e.g. ICU length of stay, hospital length of stay, ICU mortality, hospital mortality, days of mechanical ventilation) of critically-ill patients with severe COVID-19; characterising the variability in the clinical features and management strategies of these patients; exploring the risk and protective factors associated with mortality for these patients; determining variation over time in various phases of the ICU ‘journey’ including treatments received, length of stay in ICU and duration of mechanical ventilation.

Read full application


University of Oxford – International comparison of age-specific presenting symptoms for patients admitted to hospital with coronavirus disease 2019

Case definitions for COVID-19 generally require an epidemiological link demonstrating possible exposure to a case. However, as the global pandemic has spread, many countries have sustained community transmission meaning everyone is potentially exposed. For settings where microbiological testing for the causative pathogen (SARS-CoV-2) is not available, and for patients who have mild symptoms and do not seek medical attention, symptomology is the main feature for identifying possible cases. The objectives of this study are: to investigate patterns of symptoms at arrival to hospital for patients admitted to hospital with COVID-19, stratified by age, sex and country; to investigate the utility of commonly used clinical case definitions of COVID-19 for patients of different ages and in different countries.

Read full application

Associated research publication

University of Oxford – Time variation in the inpatient journey

This study addresses the following research questions: Does the ‘inpatient journey’ change over time in the course of the COVID-19 pandemic? Do patient’s presenting characteristics change in the course of the COVID-19 pandemic? Do patient’s presenting characteristics explain changes in the ‘inpatient journey’? These will be examined through exploring variation in: the overall ‘inpatient journey’, using both interactive visualization and by taking snapshots (e.g. for the first 100, 1,000, 10,000 patients, and for every 10,000-patient increment in the global dataset); time from symptom onset to hospital admission; time from hospital admission to ICU admission; length of ICU stay; time from hospital admission to oxygen supplementation; time on oxygen supplementation; length of hospital stay.

Read full application